Key facts
- Avertix (NAS: AVRT)’s last known valuation is $35.0M (Sep 2025).
- It has raised $182.5M; the latest was Later Stage VC ($30.0M) in Sep 2025.
- Notable investors include Maltese Capital Management, 1997 Corley Family Trust, Anne Arbetter Fischell Living Trust, BioInfo Accelerator, David Fischell — 17 tracked in total.
- Status: Publicly Held.
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Avertix (NAS: AVRT)
- ·The full record, as it builds
Funding rounds
No funding rounds for Avertix (NAS: AVRT) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Avertix (NAS: AVRT)
Avertix Medical Inc is a cutting-edge medical device company offering the first and only FDA-approved Class III implantable device that can detect silent and atypical symptomatic heart attacks in real-time. With a robust portfolio of U.S. patents pertaining to Acute Coronary Syndrome (ACS) events, Avertix is at the forefront of innovation in cardiovascular care and is committed to improving patient outcomes and saving lives through advanced medical technologies.
- Sector
- Healthcare
- HQ
- Eatontown, NJ, United States
- Founded
- 2001
- Employees
- 61
- Website
- avertix.com/
- Ownership
- Publicly Held
Avertix (NAS: AVRT) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Avertix (NAS: AVRT) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Avertix (NAS: AVRT) in its N-PORT filings yet. We sweep new filings monthly.